Vanguard Group Inc. Reduces Stock Position in Haemonetics Corporation $HAE

Vanguard Group Inc. reduced its position in Haemonetics Corporation (NYSE:HAE) by 2.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,834,646 shares of the medical instruments supplier’s stock after selling 118,686 shares during the quarter. Vanguard Group Inc. owned about 10.04% of Haemonetics worth $235,641,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Federated Hermes Inc. raised its position in shares of Haemonetics by 1,405.7% in the 3rd quarter. Federated Hermes Inc. now owns 46,104 shares of the medical instruments supplier’s stock valued at $2,247,000 after purchasing an additional 43,042 shares in the last quarter. Boston Partners increased its position in Haemonetics by 2.2% in the 2nd quarter. Boston Partners now owns 543,169 shares of the medical instruments supplier’s stock worth $40,660,000 after purchasing an additional 11,738 shares during the last quarter. Harbor Capital Advisors Inc. boosted its holdings in Haemonetics by 49.7% during the third quarter. Harbor Capital Advisors Inc. now owns 42,859 shares of the medical instruments supplier’s stock valued at $2,089,000 after acquiring an additional 14,226 shares during the period. Fort Washington Investment Advisors Inc. OH boosted its stake in Haemonetics by 36.2% during the third quarter. Fort Washington Investment Advisors Inc. OH now owns 706,312 shares of the medical instruments supplier’s stock worth $34,426,000 after buying an additional 187,630 shares in the last quarter. Finally, Norges Bank bought a new position in Haemonetics during the 2nd quarter valued at about $36,822,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Weiss Ratings restated a “hold (c)” rating on shares of Haemonetics in a report on Monday, December 29th. Raymond James Financial restated an “outperform” rating and issued a $90.00 target price on shares of Haemonetics in a research note on Friday, November 14th. Barrington Research set a $94.00 price objective on Haemonetics in a research note on Friday, February 6th. BTIG Research restated a “buy” rating and set a $88.00 price objective on shares of Haemonetics in a research report on Friday, February 6th. Finally, Wall Street Zen upgraded shares of Haemonetics from a “hold” rating to a “buy” rating in a research report on Saturday, January 10th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $84.44.

Haemonetics Stock Up 1.7%

Shares of NYSE HAE opened at $63.28 on Monday. The company has a current ratio of 1.75, a quick ratio of 1.15 and a debt-to-equity ratio of 1.01. The firm has a market capitalization of $2.94 billion, a PE ratio of 17.43, a price-to-earnings-growth ratio of 1.32 and a beta of 0.28. The firm’s 50-day moving average is $70.13 and its 200-day moving average is $64.19. Haemonetics Corporation has a 1 year low of $47.31 and a 1 year high of $87.32.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, February 5th. The medical instruments supplier reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.27 by $0.04. The company had revenue of $338.97 million during the quarter, compared to the consensus estimate of $331.90 million. Haemonetics had a net margin of 13.31% and a return on equity of 27.32%. The company’s quarterly revenue was down 2.7% on a year-over-year basis. During the same quarter last year, the firm posted $1.19 EPS. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. Equities analysts expect that Haemonetics Corporation will post 4.55 EPS for the current year.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.